No profile data available.
Parabilis Medicines, Inc. (PBLS) is a listed company, based in Cambridge, United States, with about 145 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$186.93 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $148,000. Its market capitalization was $3.39 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable.
Parabilis Medicines reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $148,000.
$3.39 billion as of October 9, 2026.